Cover Image
市場調查報告書 - 200950

生殖器濕疣(尖頭濕疣)開發中產品分析

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015

出版商 Global Markets Direct
出版日期 內容資訊 英文 67 Pages
價格
生殖器濕疣(尖頭濕疣)開發中產品分析 Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015
出版日期: 2015年05月13日 內容資訊: 英文 67 Pages
簡介

生殖器濕疣(尖頭濕疣)是一般最常見的性行為感染疾病之一。積極從事性活動的人半數以上在一生的某個時刻,會感染到引起生殖器濕疣的病毒。如名字所示,生殖器濕疣對性器官潮濕的組織起作用。生殖器濕疣的外表,為小型肉色疙瘩的形式(或菜花狀外形)。大多數場合,疙瘩非常小,肉眼無法辨識。

本報告提供全球各國的生殖器濕疣 (尖頭濕疣)治療用開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗各階段產品的一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

生殖器濕疣概要

治療藥的開發

  • 生殖器濕疣的開發中產品:概要
  • 生殖器濕疣的開發中產品:比較分析

各企業開發中的生殖器濕疣治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

生殖器濕疣治療藥:開發中產品一覽(各企業)

生殖器濕疣治療藥的開發企業

  • Helix BioPharma Corp.
  • Inovio Pharmaceuticals, Inc
  • NanoViricides, Inc
  • G&E Herbal Biotechnology Co., Ltd.
  • Anaconda Pharma
  • Foamix Ltd
  • Telormedix SA
  • Genetic Immunity, Inc
  • Xiamen Amoytop Biotech Co., Ltd

生殖器濕疣:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • 干擾素α-2b
  • SRT-100
  • AP-611074
  • TMX-202
  • INO-3112
  • HerpeCide-I
  • 干擾素α-2b
  • imiquimod
  • HupaDerm疫苗

生殖器濕疣治療藥:最新的藥物簡介

生殖器濕疣治療藥:暫停開發的產品

生殖器濕疣治療藥:停止開發的產品

生殖器濕疣相關產品開發的里程碑

  • 值得注意的最新趨勢、新聞稿(共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015', provides an overview of the Genital Warts (Condylomata Acuminata)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Genital Warts (Condylomata Acuminata) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Warts (Condylomata Acuminata) Overview
  • Therapeutics Development
    • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview
    • Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis
  • Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Genital Warts (Condylomata Acuminata) - Products under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development
    • Agilvax, Inc.
    • Anaconda Pharma
    • Biogenomics Limited
    • BioMAS Ltd.
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Helix BioPharma Corp.
    • LEO Pharma A/S
    • MediGene AG
    • NanoViricides, Inc.
    • Novan, Inc.
    • Tamir Biotechnology, Inc.
  • Genital Warts (Condylomata Acuminata) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-611074 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AX-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HerpeCide-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa-2b (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alpha-2b (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sinecatechins - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates
  • Genital Warts (Condylomata Acuminata) - Dormant Projects
  • Genital Warts (Condylomata Acuminata) - Discontinued Products
  • Genital Warts (Condylomata Acuminata) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries
      • Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries
      • Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen
      • Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland
      • Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen in United Kingdom and Ireland
      • Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden
      • Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia
      • Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan
      • Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada
      • Jul 29, 2013: Medigene: Market launch of Veregen in the Netherlands started
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015
  • Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by MediGene AG, H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2015
  • Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2015
  • Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2015
  • Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015
  • Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top